Tetrahedron 68 (2012) 173-178

Contents lists available at SciVerse ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

I_2 /CuO-catalyzed tandem cyclization strategy for one-pot synthesis of substituted 2-aminothiozole from easily available aromatic ketones/ α , β -unsaturated ketones and thiourea

Yan-Ping Zhu, Jing-Jing Yuan, Qin Zhao, Mi Lian, Qing-He Gao, Mei-Cai Liu, Yan Yang, An-Xin Wu*

Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, Central China Normal University, Wuhan 430079, China

ARTICLE INFO

Article history: Received 18 July 2011 Received in revised form 15 October 2011 Accepted 21 October 2011 Available online 28 October 2011

Keywords: 2-Aminothiazole One-pot reaction Tandem cyclization α-Halogenation ketones I₂/CuO

ABSTRACT

A concise and efficient one-pot process from easily available methyl ketones/unsaturated methyl ketones and thiourea was developed for the synthesis of 2-aminothiazoles under the media of I_2/CuO . The method can highly stereoselectivity obtain the E-isomers of 4-ethenyl-2-aminothiazoles (**5a**–**f**). All these target molecules were characterized by NMR, HRMS and IR spectra. Furthermore, the target compounds **3c** and **5b** were further determined by X-ray crystallographic analysis.

© 2011 Elsevier Ltd. All rights reserved.

Tetrahedror

1. Introduction

Thiazole as useful structural element plays an important role in nature and has broad applications in the field of agriculture and medicinal chemistry.¹ Thiazole ring is a main structural motif of many natural compounds such as vitamin B1 (thiamine), penicillin and carboxylase.

Moreover 2-aminothiazoles as important precursors have been employed in the preparation of different important drugs required for the treatment of allergies, hypertension, inflammation, schizophrenia, bacterial, and HIV infections.² Therefore, much attention has been paid to the synthesis of 2-aminothiazoles, for which the general approaches include condensation of α -bromoketone with thiourea,³ the reaction of α -thiocyanato carbonyl compounds with aromatic or aliphatic aminehydrochlorides,⁴ treatment of stylene and thiourea with NBS⁵ and condensation of aromatic ketone and thiourea with solid supported catalyst or heterogeneous catalyst.⁶

In recent years, tandem, multicomponent, and one-pot reactions have attracted much attention as powerful and useful synthetic tools in synthetic chemistry and drug discovery. These reactions, by virtue of their atom-economy, reducing the number of operations, and saving reagents, energy, time, and labour, have been used in many chemical transformations.⁷

In our previous studies, we proposed a novel method for the synthesis of α -iodo ketones and α , β -unsaturated α' -iodo ketones (Scheme 1) on the basis of aromatic ketones and α , β -unsaturated ketones under the media of I_2/CuO .⁸ Moreover, α -halogenation ketones as important precursors have been employed in the preparation of various heterocycles.⁹ Therefore, we considered the possibility of catalyzing aromatic ketones in situ obtained α -iodo ketones, which can react with thiourea in one-pot to afford 2-aminothiazole under the media of I_2/CuO . If successful, this would simplify the synthetic steps, and develop a novel synthetic method for the synthesis of 2-amino-4-arylthiazole and 2-amino-4-ethenylthiazole derivatives.



Scheme 1. Synthesis of α -iodo ketones and α , β -unsaturated α' -iodo ketones on the basis of aromatic ketones and α , β -unsaturated ketones under the media of I_2/CuO .

Herein, we present a concise, rapid and efficient method for preparation of substituted 2-aminothiazole from easily available aromatic ketones and thiourea. In addition, this method can also synthesize 2-amino-4-ethenylthiazole derivatives efficiently.



^{*} Corresponding author. Tel./fax: +86 (0)27 67867773; e-mail address: chwuax@ mail.ccnu.edu.cn (A.-X. Wu).

^{0040-4020/\$ –} see front matter @ 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2011.10.074

2. Results and discussion

To initiate our study, we first tested the reaction of α -iodo ketone with thiourea in MeOH at reflux. To our delight, the product was obtained in 95% yield (Scheme 2).



Scheme 2. Formation of 2-amino-4-arylthiazole via the condensation of α -iodo ketone with thiourea in MeOH at reflux.

With the success in obtaining substituted 2-aminothiazole from phenacyl iodine with thiourea, we wondered whether it would be possible to integrate the two processes (Schemes 1 and 2) in a onepot reaction. Therefore, we optimized the reaction conditions for the formation of 2-aminothiazole with aryl methyl ketones (1a) and thiourea (2) as substrates (Table 1). Various solvents were first examined. The product was not obtained when acetonitrile (MeCN), tetrahydrofuran (THF), toluene or dimethylformamide (DMF) was used as solvent. It was notable, however, that this transformation occurred smoothly in MeOH, with 88% yield. And product 3a was obtained in moderate to good yields using methanol, propanol and butanol as solvents. However, no reaction occurred in tert-butanol in the conditions. It was obvious that ethanol was the optimal solvent in the reaction. Next, the molar ratio of substrate, I₂ and CuO was also optimized. When the molar ratio of $n(1a)/n(2)/n(CuO)/n(I_2)$ was varied from 1:1:1:1 to 1:1.1:1.1 (entries 6, 10–12), the reaction afforded the product **3a** in 86–90% yield in ethanol at reflux. It was obvious that $n(1a)/n(2)/n(I_$ n(CuO)=1:1:1.1:1.1 is the optimal condition. Finally, the effect of reaction temperature on the yield of the product 3a was also examined. The experiment result indicates that 78 °C is the optimal temperature.

To assess the generality of this method and to evaluate the electronic influence of the aromatic ring substituents, a series of other aromatic ketones **1b**–**m** were examined under the optimal conditions (Table 2). While the benzene rings bore electron-

Table 1

Effect of solvent, temperature and molar ratio of $n(1a)/n(2)/n(L_2)/n(CuO)$ on the yield of 3a

	+ H ₂ N NH ₂	I ₂ , CuO Condition	S N N 3a
Entry	Solvent/(°C)	$n(\mathbf{1a})/n(2)/n(I_2)/n(CuO)$	Yield ^a (%)
1	MeCN/82	1:1:1:1	0 ^b
2	THF/66	1:1:1:1	0 ^b
3	DMF/90	1:1:1:1	0 ^b
4	Toluene/111	1:1:1:1	0 ^b
5	MeOH/65	1:1:1:1	85
6	EtOH/78	1:1:1:1	88
7	PrOH/97	1:1:1:1	75
8	BuOH/118	1:1:1:1	70
9	t-BuOH/83	1:1:1:1	0 ^b
10	EtOH/78	1:1:1.1:1	90
11	EtOH78	1:1:1.5:1.5	88
12	EtOH/78	1:1.1:1.1:1.1	86
13	EtOH/65	1:1:1.1:1.1	75
14	EtOH/55	1:1:1.1:1.1	50

^a Isolated yield.

^b No reaction.

Table 2

Formation of 2-amino-4-arylthiazole via the tandem reaction of methyl ketones and thiourea under the media of I_2/CuO^a

R +	$H_2N \xrightarrow{S} H_2 N H_2 \frac{I_2, CuC}{Conditio}$	n R	S NH ₂ 3
Entry	Substrates (R=)	Product	Yield ^b (%)
1	C ₆ H ₅ (1a)	3a	90
2	$4-Me-C_{6}H_{5}(\mathbf{1b})$	3b	88
3	$4-Me-OC_{6}H_{5}(1c)$	3c	92
4	3,4-OCH ₂ O-C ₆ H ₅ (1d)	3d	85
5	$2,4-OMe_2-C_6H_5$ (1e)	3e	86
6	$4-Cl-C_{6}H_{5}(\mathbf{1f})$	3f	80
7	$4-Br-C_{6}H_{5}(1g)$	3g	72
8	$3-O_2N-C_6H_5(1h)$	3h	48
9	$4-Ph-C_{6}H_{5}(1i)$	3i	68
10	2-Naph—C ₆ H ₅ (1j)	3j	65
11	$4-HO-C_{6}H_{5}(\mathbf{1k})$	3k	50
12	2-Furan—C ₆ H ₅ (11)	31	75
13	2-Thinyl–C ₆ H ₅ (1m)	3m	72

^a Standard conditions: *n*(**1**)/*n*(**2**)/*n*(L₂)/*n*(CuO)=1:1:1.1:1.1, *T*=78 °C.

^b Isolated yield.

donating groups (e.g., 4-Me, 4-OMe, 2,4-OMe₂), the corresponding products **3b–e** were obtained in good yields (85–92%, entries 2-5, Table 2). And when the benzene rings substituted with electron-withdrawing groups (e.g., 4-Cl, 4-Br, 3-NO₂, 4-Ph), the corresponding products **3b**-**k** were obtained in moderate to good yields (48-80%, entries 6-9, Table 2). It should be noted that an electron-donating substituent on the benzene ring caused a considerable increase in the yield. 2-Naphthyl methyl ketone (1k) also gave satisfying result. To our great satisfaction, sensitive hydroxy group (OH) was not affected under these mild reaction conditions, and the expected product 3k was obtained in 50% yield. Encouraged by the results obtained with aryl methyl ketones, we turned our attention to the heteroaryl ketones. The heterocycle, including furan (11) and thiophen (1m), did not affect the overall efficiency, and the corresponding products **31** and **3m** were obtained in 75% and 72% yields, respectively.

To further expand scope of the ketone, unsaturated methyl ketones such as **4a**–**f** were also investigated.¹⁰ Under the optimal conditions, the corresponding ethenyl 2-aminothiazoles could be obtained with a slightly lower yield of 45–63%. The possible reason for the low yield was that C=C bond reduced the conjugate effect of aromatic cycles and acetyl group. So, the α -iodination was not easy to achieve in the first step. For further investigation, the reactions with unsaturated methyl ketones such as benzalacetone (**4g**) and 4phenylbut-3-yn-2-one (**4h**) could not afford the desired product. It should be noted that an electron-donating substituent on the benzene ring caused a considerable increase in the yield than an electron-withdrawing substituent, which was consistent with aryl methyl ketones. In all cases, only the thermodynamically stable *E*isomers were obtained. It has a high stereoselectivity (Table 3).

After successful exploration of the scope of the reaction towards reactants, the aromatic ketones/ α , β -unsaturated ketones and thiourea, we turned our attention to other types of ketones and thioureas. Accordingly, the substituted *N*-methylthiourea was investigated; all the aromatic ketones smoothly underwent the transformation with *N*-methylthiourea to provide the *N*-methyl aminothiazoles (**7a**–**c**) in good yields (70–78% yields, Table 4). Next, 1,3-diketone (1,3-bis(4-methoxyphenyl)propane-1,3-dione) was also investigated, the desired product was obtained in 72% yield. In addition, the scope of the reaction was further demonstrated by reacting β -ketoesters (**6e**–**j**) under the optimized conditions. The results collected (Table 4) point out the facts that both

Table 3

Formation of 2-amino-4-ethenylthiazoles via the tandem reaction of $\alpha,\beta\text{-unsaturated}$ methyl ketones^a



-					
	Entry	Substrates (R=)	Product	Isolated yield ^b (%)	trans ^c (%)
	1	C_6H_5 (4a)	5a	60	>99
	2	4-Me-C ₆ H ₅ (4b)	5b	58	>99
	3	4-MeO-C ₆ H ₅ (4c)	5c	62	>99
	4	3,4-(MeO) ₂ -C ₆ H ₅ (4d)	5d	63	>99
	5	$4-NO_2-C_6H_5(4e)$	5e	45	>99
	6	$3-NO_2-C_6H_5(4f)$	5f	48	>99
	7	$(E)-C_{6}H_{5}-CH=CH-(4g)$	5g	0^{d}	_
	8	$C_6H_5-CH\equiv CH-(4h)$	5h	0 ^d	_

^a Standard conditions: *n*(**1**)/*n*(**2**)/*n*(I₂)/*n*(CuO)=1:1:1.1:1.1, *T*=78 °C.

^b Isolated yield.

^c Determined by ¹H NMR of the crude product.

^d No reaction occurred.



^a Standard conditions: *n*(**6**)/*n*(**2**)/*n*(I₂)/*n*(CuO)=1:1:1.1:1.1, *T*=78 °C.

^b Isolated yield.

electron-withdrawing and electron-donating groups at aromatic cycles are tolerated. To our great satisfaction, the heterocycle (furan) was not affected under these mild reaction conditions, and the expected product **7j** was obtained in 50% yield. Other aliphatic ketones (3,3-dimethylbutan-2-one, 3-methylbutan-2-one and butan-2-one), hexamethylketone and hexamethyldiketone were also investigated under the optimal conditions. Unfortunately, the reaction could not be performed.

All these target molecules were characterized by NMR, MS and IR spectra. Furthermore, the target compounds **3c** (See

A possible mechanism of the present reaction could be described as follows using acetophenone (**1a**) as an example (Scheme 3): Initially, the acetophenone **1a** undergoes the formation of enolate ion **A** under basic conditions, and **A** converts to **B** or its enolizational isomer **C** in the media of I₂ and CuO. Subsequently, CuO catalyses **B** converting to **D**, CuI, H₂O and regenerated I₂. Then, **G** is obtained undergoing intermolecular nucleophilic substitute of **D** with thiourea enolizational isomer **F**. **G** undergoing an intramolecular nucleophilic addition transforms into **H**, which converts to **I** via dehydration. Finally, intermediate **I** undergoes neutralization reaction

Supplementary data page 7) and **5b**¹¹ were further determined by X-ray crystallographic analysis. In the crystal structure of compound **5b**, the bond distance of C8–C9 and the torsion angle of C(5)-C(8)-C(9)-C(10) are 1.32 Å and -179.69° , respectively, which supports the *E*-configuration of the olefin **5b** (Fig. 1).



Fig. 1. The X-ray crystal structure of compound 5b.



Scheme 3. The proposed mechanism for the transformation.

to furnish the desired product in the presence of CuO. In addition, regenerated I_2 can catalyse the transformation of **A** to **B** again.

3. Conculsion

In conclusion, a concise and efficient one-pot process from easily available methyl ketones/unsaturated methyl ketones, 1,3-diketone, β -ketoesters and thioureas was developed for the synthesis of 2-aminothiazoles under the media of I₂/CuO. In addition, the method can highly stereoselectivity obtain the E-isomers of 4-ethenyl-2-aminothiazoles (**5a**-**f**). Further application of this methodology for the synthesis of various heterocyclic compounds is under way in our laboratory.

4. Experimental

4.1. General method

All aryl methyl ketones (**1a**–**m**), thiourea (**2**) and other reagents were obtained from commercial suppliers and used without further purification. TLC analysis was performed using pre-coated glass plates. Column chromatography was performed using silica gel (200–300 mesh). IR spectra were recorded on a Perkin–Elmer PE-983 infrared spectrometer as KBr pellets with absorption in cm⁻¹. NMR spectra were recorded on a Varian Mercury 400 or 600 MHz spectrometer. Chemical shifts are reported in ppm, relative to the internal standard of tetramethylsilane (TMS). HRMS were obtained on a Bruker 7-tesla FT-ICR MS equipped with an electrospray source. The X-ray crystal structure determinations of **1a** and **5a** were obtained on a Bruker SMART APEX CCD system.

4.2. General procedure for preparation of 3 and 5 (3a as an example)

A mixture of acetophenone **1a** (120 mg, 1 mmol), iodine (279.2 mg, 1.1 mmol), and CuO (88 mg, 1.1 mmol) in anhydrous ethanol (30 mL) was heated at reflux, after disappearance of the reactant (1–12 h, monitored by TLC), thiourea **2** (76 mg, 1 mmol) was added and the mixture was refluxed for 1 h. After that, the solvent was removed under reduce pressure, and added 50 mL water to the residue, then extracted with EtOAc three times (3×50 mL). The extract was washed with 10% Na₂S₂O₃ then a small amount 5% NaOH solution, dried over anhydrous Na₂SO₄ and

concentrated in vacuo. The residue was purified by column chromatography on silica gel using petroleum ether/EtOAc as the eluent to give the expected products **3a** in 90% yield.

4.3. Spectroscopic data

4.3.1. 4-Phenylthiazol-2-amine (**3a**). IR (KBr): 3434, 3248, 3113, 1598, 1516, 1481, 1440, 1330, 1306, 1199, 1070, 1038, 1021 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.75 (d, *J*=7.8 Hz, 2H), 7.36–7.38 (t, *J*=7.8 Hz, 2H), 7.27–7.29 (t, *J*=7.8 Hz, 1H), 5.49 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =167.5, 151.1, 134.6, 128.6, 127.7, 126.0, 102.7; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₉H₉N₂S: 177.0418; found: 177.0477.

4.3.2. 4-*p*-Tolylthiazol-2-amine (**3b**). IR (KBr): 3453, 3298, 3117, 1637, 1538, 1521, 1489, 1333, 1037 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.64 (d, *J*=8.4 Hz, 2H), 7.17 (d, *J*=8.4 Hz, 2H), 6.62 (s, 1H), 5.54 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =167.7, 151.2, 137.4, 131.9, 129.2, 125.8, 101.7, 21.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₀H₁₁N₂S: 191.0637; found: 191.0632.

4.3.3. 4-(4-Methoxyphenyl)thiazol-2-amine (**3c**). IR (KBr): 3438, 3267, 3117, 2964, 2934, 2834, 1626, 1606, 1537, 1519, 1492, 1290, 1245, 1177, 1035 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =7.73 (d, *J*=9.0 Hz, 2H), 7.01 (s, 2H), 6.93 (d, *J*=9.0 Hz, 2H), 3.78 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =168.2, 158.7, 149.9, 128.0, 127.0, 114.0, 100.0, 55.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₀H₁₁N₂SO: 207.0587; found: 207.0581.

4.3.4. 4-(1,3-Dihydroisobenzofuran-5-yl)thiazol-2-amine (**3d**). IR (KBr): 3431, 3298, 3122, 2900, 1639, 1539, 1498, 1481, 1449, 1331, 1291, 1242, 1195, 1122, 1039 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ =7.38 (s, 2H), 7.08 (s, 2H), 6.91–6.95 (m, 2H), 6.07 (s, 2H), 3.48 (s, 2H); ¹³C NMR (150 MHz, DMSO-*d*₆): δ =168.1, 149.5, 147.5, 146.4, 129.5, 119.4, 108.3, 105.9, 101.0, 100.1; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₁H₁₃N₂O₂S: 237.0692; found: 237.0690.

4.3.5. 4-(2,4-Dimethoxyphenyl)thiazol-2-amine (**3e**). IR (KBr): 3382, 3287, 3113, 2924, 1609, 1579, 1533, 1463, 1434, 1291, 1211, 1160, 1127, 1069, 1050 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.94 (d, *J*=8.4 Hz, 1H), 7.25 (s, 1H), 6.51–6.54 (m, 2H), 5.31 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =165.8, 160.0, 157.8,

146.5, 130.5, 116.6, 105.2, 104.4, 98.7, 55.3; HRMS (ESI): $m/z \,[M+H]^+$ calcd for C₁₁H₁₃N₂O₂S: 237.0692; found: 237.0690.

4.3.6. 4-(4-Chlorophenyl)thiazol-2-amine (**3f**). IR (KBr): 3438, 3283, 3112, 1633, 1534, 1476, 1401, 1338, 1088 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =7.83 (d, J=9.0 Hz, 2H), 7.43 (d, J=9.0 Hz, 2H), 6.90 (s, 2H), 7.06 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =168.6, 148.6, 133.7, 131.8, 128.7, 127.4, 102.5; HRMS (ESI): m/z [M+H]⁺ calcd for C₉H₈N₂SCl: 211.0091; found: 211.0086.

4.3.7. 4-(4-Bromophenyl)thiazol-2-amine (**3g**). IR (KBr): 3428, 3282, 3111, 2926, 1633, 1534, 1472, 1396, 1336, 1198, 1068, 1037, 1006 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =7.76 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.16 (s, 2H), 7.07 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =168.5, 148.8, 134.2, 131.5, 127.7, 120.3, 102.6; HRMS (ESI): m/z [M+H]⁺ calcd for C₉H₈N₂SBr: 254.9586; found: 254.9583.

4.3.8. 4-(3-Nitrophenyl)thiazol-2-amine (**3h**). IR (KBr): 3423, 3291, 3110, 1636, 1537, 1514, 1473, 1344, 1259, 1205, 1050 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =8.63 (s, 1H), 8.25 (d, *J*=7.8 Hz, 1H), 8.12 (d, *J*=7.8 Hz, 1H), 7.67–7.69 (t, *J*=7.8 Hz, 1H), 7.35 (s, 1H), 7.25 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =168.6, 148.3, 147.5, 136.4, 131.6, 130.1, 121.8, 120.0, 104.3; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₇H₇N₂OS: 222.0332; found: 222.0332.

4.3.9. 4-([1,1'-Biphenyl]-4-yl)thiazol-2-amine (**3i**). IR (KBr): 3438, 3289, 3109, 1631, 1524, 1480, 1405, 1332, 1306, 1198, 1041 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =7.91 (d, J=8.4 Hz, 2H), 7.68–7.73 (m, 4H), 7.46–7.48 (t, J=7.8 Hz, 2H), 7.35–7.39 (t, J=7.8 Hz, 1H), 7.12 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =168.3, 149.6, 139.8, 138.8, 134.1, 129.0, 127.5, 126.8, 126.5, 126.2, 101.9; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₅H₁₃N₂S: 253.0794; found: 253.0790.

4.3.10. 4-(Naphthalen-2-yl)thiazol-2-amine (**3***j*). IR (KBr): 3423, 3248, 3111, 2925, 2856, 1599, 1525, 1494, 1361, 1321, 1182, 1037 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ =8.36 (s, 1H), 7.89–7.98 (m, 5H), 7.49–7.53 (m, 2H), 7.18 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =168.3, 149.8, 133.3, 132.3, 128.2, 128.0, 127.6, 126.4, 126.0, 124.1, 102.5; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₃H₁₁N₂S: 227.0637; found: 222.0632.

4.3.11. 4-(2-Aminothiazol-4-yl)phenol (**3k**). IR (KBr): 3449, 3304, 3199, 3120, 2654, 2588, 1622, 1539, 1515, 1436, 1339, 1265, 1245, 1180, 1033 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6): δ =9.58 (s, 1H), 7.64 (s, 2H), 7.07 (s, 2H), 6.81 (s, 2H), 6.73 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =168.3, 156.9, 149.9, 127.1, 126.3, 115.4, 98.8; HRMS (ESI): m/z [M+H]⁺ calcd for C₉H₉N₂OS: 193.0430; found: 193.0427.

4.3.12. 4-(*Furan-2-yl*)*thiazol-2-amine* (**3l**). IR (KBr): 3436, 3271, 3106, 2960, 1627, 1527, 1453, 1389, 1333, 1204, 1150, 1047, 1008 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ =7.64 (s, 1H), 7.14 (s, 2H), 6.74 (s, 1H), 6.54 (d, *J*=4.8 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =168.7, 150.6, 142.2, 141.8, 111.6, 106.0, 100.6; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₇H₇N₂OS: 167.0274; found: 167.0270.

4.3.13. 4-(*Thiophen-2-yl*)*thiazol-2-amine* (**3m**). IR (KBr): 3425, 3269, 3100, 2928, 1622, 1551, 1520, 1364, 1317, 1285, 1186, 1079, 1050 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.31 (d, *J*=3.0 Hz, 1H), 7.21 (d, *J*=4.8 Hz, 1H), 7.01–7.02 (t, *J*=4.2 Hz, 1H), 5.54 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =167.7, 145.4, 138.6, 127.6, 124.5, 123.4, 123.3, 101.3; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₇H₇N₂S₂: 183.0045; found: 183.0042.

4.3.14. (E)-4-Styrylthiazol-2-amine (**5a**). IR (KBr): 3478, 3377, 3287, 3092, 3024, 1636, 1599, 1538, 1522, 1444, 1343, 1292, 1124, 1072,

960 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ =7.48 (d, *J*=7.2 Hz, 2H), 7.32–7.34 (t, *J*=7.8 Hz, 2H), 7.24 (d, *J*=16.2 Hz, 1H), 8.86 (d, *J*=16.2 Hz, 1H), 5.24 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =167.3, 150.2, 137.1, 130.3, 128.6, 127.6, 126.5, 121.4, 106.6; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₁H₁₁N₂S: 203.0637; found: 203.0634.

4.3.15. (*E*)-4-(4-Methylstyryl)thiazol-2-amine (**5b**). IR (KBr): 3410, 3282, 3112, 3019, 2918, 1616, 1533, 1512, 1352, 1295, 1124, 967 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.36–7.37 (d, *J*=6.6 Hz, 2H), 7.19–7.22 (d, *J*=15.6 Hz, 1H), 7.13–7.14 (d, *J*=6.6 Hz, 2H), 6.80–6.83 (d, *J*=15.6 Hz, 1H), 5.31 (s, 2H), 2.34 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =167.4, 150.3, 137.4, 134.3, 130.2, 129.3, 126.4, 120.5, 106.1, 21.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₂H₁₃N₂OS: 233.0743; found: 233.0743.

4.3.16. (*E*)-4-(4-Methoxystyryl)thiazol-2-amine (**5c**). IR (KBr): 3428, 3267, 3118, 2962, 2931, 2836, 1624, 1603, 1535, 1514, 1417, 1347, 1304, 1266, 1239, 1176, 1110, 1024, 963 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.41 (d, *J*=8.4 Hz, 2H), 7.12–7.20 (d, *J*=15.6 Hz, 1H), 6.86–6.88 (d, *J*=7.8 Hz, 2H), 6.72–6.75 (d, *J*=15.6 Hz, 1H), 5.25 (s, 2H), 3.81 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =167.3, 159.2, 150.2, 129.8, 128.8, 127.7, 119.3, 114.0, 105.5, 89.6, 55.2; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₃N₂OS: 233.0743; found: 233.0743.

4.3.17. (*E*)-4-(3,4-Dimethoxystyryl)thiazol-2-amine (**5d**). IR (KBr): 3415, 3292, 3146, 3109, 2967, 2932, 2833, 1631, 1538, 1514, 1495, 1462, 1417, 1349, 1260, 1221, 1156, 1135, 1026 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =7.17–7.19 (d, *J*=16.8 Hz, 1H), 7.02–7.03 (d, *J*=6.6, Hz, 2H), 6.83–6.84 (d, *J*=8.4 Hz, 1H), 6.74–6.76 (d, *J*=16.8 Hz, 1H), 6.39 (s, 1H), 5.29 (s, 2H), 3.91 (s, 3H), 3.89 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =167.4, 150.3, 148.9, 148.8, 130.0, 119.9, 119.7, 111.0, 108.5, 105.7, 55.8; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₂H₁₃N₂OS: 233.0743; found: 233.0743.

4.3.18. (*E*)-4-(4-Nitrostyryl)thiazol-2-amine (**5e**). IR (KBr): 3418, 2959, 2925, 2854, 1726, 1628, 1589, 1514, 1340, 1288, 1106, 1075 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.18–8.20 (d, *J*=8.4 Hz, 2H), 7.77–7.78 (d, *J*=8.4 Hz, 2H), 7.23–7.26 (d, *J*=15.6 Hz, 1H), 7.15–7.18 (d, *J*=15.6 Hz, 1H), 6.82 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =168.2, 149.3, 145.9, 144.3, 129.5, 127.0, 126.3, 124.1, 109.6; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₂H₁₃N₂OS: 233.0743; found: 233.0743.

4.3.19. (*E*)-4-(3-*Nitrostyryl*)*thiazol-2-amine* (**5***f*). IR (KBr): 3407, 3103, 2926, 1725, 1633, 1536, 1519, 1350, 1125 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.33 (s, 1H), 8.07–8.08 (q, *J*=7.8 Hz, 1H), 7.96–7.97 (d, *J*=7.8 Hz, 1H), 7.63–7.65 (t, *J*=7.8 Hz, 1H), 7.20–7.23 (d, *J*=15.6 Hz, 1H), 7.15–7.18 (d, *J*=15.6 Hz, 1H), 7.10 (s, 2H), 6.76 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =168.3, 149.3, 148.5, 139.3, 132.8, 130.4, 126.3, 125.5, 121.8, 120.3, 108.5; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₃N₂OS: 233.0743; found: 233.0743.

4.3.20. *N*-*Methyl*-4-*phenylthiazol*-2-*amine* (**7a**). IR (KBr): 3444, 3225, 3116, 2918, 1588, 1482, 1403, 1330, 1072, 1059 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.78 (d, *J*=7.2 Hz, 2H), 7.35–7.39 (t, *J*=7.2 Hz, 2H), 7.29 (s, 1H), 6.92 (s, 2H), 6.66 (s, 1H), 2.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =171.5, 151.6, 135.1, 128.5, 127.6, 126.0, 100.4, 32.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₀H₁₁N₂S: 191.06375; found: 191.06313.

4.3.21. 4-(4-Methoxyphenyl)-N-methylthiazol-2-amine (**7b**). IR (KBr): 3275, 3111, 2923, 1715, 1578, 1534, 1492, 1463, 1396, 1330, 1303, 1251, 1182, 1108, 1055, 1029 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.68 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.4 Hz, 2H), 6.83 (s, 1H), 6.53 (s, 1H), 3.82 (s, 3H), 2.77 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =159.3, 127.6, 127.3, 113.9, 98.6, 55.2, 32.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₁H₁₃N₂OS: 221.07431; found: 211.0738.

4.3.22. 4-(4-Bromophenyl)-N-methylthiazol-2-amine (**7c**). IR (KBr): 3443, 3265, 1581, 1567, 1474, 1451, 1394, 1325, 1268, 1121, 1071, 1008 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.65 (d, *J*=8.8 Hz, 2H), 7.49 (d, *J*=8.4 Hz, 2H), 6.68 (s, 1H), 6.35 (s, 1H), 2.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =171.3, 150.3, 133.8, 131.6, 127.6, 121.5, 101.1, 32.2; HRMS (ESI): *m*/*z* [M+H]⁺ calcd for C₁₀H₁₀BrN₂S: 268.97426; found: 268.97392.

4.3.23. (2-Amino-4-(4-methoxyphenyl)thiazol-5-yl)(4-methoxyphenyl)methanone (**7d**). IR (KBr): 3310, 3071, 2961, 2833, 1709, 1643, 1606, 1585, 1568, 1510, 1471, 1433, 1330, 1299, 1248, 1172, 1124, 1071, 1033 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =7.90 (s, 2H), 7.42 (d, *J*=7.6 Hz, 2H), 7.24 (d, *J*=7.6 Hz, 2H), 6.72 (d, *J*=7.6 Hz, 2H), 6.68 (d, *J*=7.6 Hz, 2H), 3.72 (s, 3H), 3.68 (s, 3H); ¹³C NMR (100 MHz, DMSO): δ =186.4, 170.2, 161.8, 159.3, 131.0, 113.1, 112.9, 55.3, 55.1; HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₇N₂O₃S: 341.09544; found: 341.09510.

4.3.24. Ethyl 2-amino-4-phenylthiazole-5-carboxylate (**7e**). IR (KBr): 3396, 3285, 3095, 2979, 1658, 1635, 1516, 1481, 1448, 1369, 1340, 1303, 1170, 1091 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =7.89 (s, 2H), 7.66–7.69 (m, 2H), 7.37–7.39 (m, 2H), 4.09–4.13 (m, 2H), 1.13–1.17 (t, *J*=7.2 Hz, 3H); ¹³C NMR (100 MHz, DMSO): δ =170.0, 161.2, 158.8, 134.7, 129.7, 128.7, 127.3, 108.5, 60.1, 14.1; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₃O₂N₂S: 249.06922; found: 249.06878.

4.3.25. Ethyl 2-amino-4-(3,4-dimethoxyphenyl)thiazole-5carboxylate (**7f**). IR (KBr): 3366, 3112, 2971, 2939, 1705, 1639, 1520, 1302, 1255, 1228, 1183, 1138, 1076, 1025 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.35 (d, *J*=8.8 Hz, 1H), 7.31 (s, 1H), 6.90 (d, *J*=8.0 Hz, 1H), 5.85 (s, 2H), 4.19–4.24 (q, *J*=14.0 Hz, 2H), 3.92 (s, 6H), 1.25–1.28 (t, *J*=7.2 Hz, 3H); ¹³C NMR (100 MHz, DMSO): δ =168.82, 161.71, 158.45, 149.74, 126.61, 122.96, 112.89, 110.84, 110.11, 60.79, 55.90, 55.85, 14.28; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₄H₁₇O₄N₂S: 309.09035; found: 309.09021.

4.3.26. Ethyl 2-amino-4-(4-bromophenyl)thiazole-5-carboxylate (**7g**). IR (KBr): 3413, 3289, 3107, 1984, 1668, 1642, 1524, 1478, 1394, 1368, 1309, 1170, 1091, 1013 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =7.90 (s, 2H), 7.60 (s, 4H), 4.08–4.12 (m, 2H), 1.15–1.18 (t, *J*=6.8 Hz, 3H); ¹³C NMR (100 MHz, DMSO): δ =175.16, 166.23, 162.50, 138.90, 136.92, 135.51, 127.14, 113.8, 65.36, 19.28; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₂BrF₆O₂N₂S: 328.97974; found: 328.97726.

4.3.27. *Ethyl 2-amino-4-(4-nitrophenyl)thiazole-5-carboxylate* (**7h**). IR (KBr): 3411, 3128, 1707, 1648, 1600, 1519, 1482, 1346, 1279, 1159, 1113, 1071 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =8.24 (s, 2H), 7.91 (s, 4H), 4.11 (s, 2H), 1.16 (s, 3H); ¹³C NMR (100 MHz, DMSO): δ =170.2, 160.9, 155.7, 147.2, 140.9, 131.0, 122.6, 60.5, 14.0; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₂H₁₂N₃O₄S: 294.05430; found: 294.05400.

4.3.28. Ethyl 2-amino-4-(3,5-bis(trifluoromethyl)phenyl)thiazole-5carboxylate (**7i**). IR (KBr): 3368, 3139, 1662, 1645, 1516, 1464, 1380, 1308, 1278, 1168, 1130, 1080, 1017 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =8.37 (d, *J*=6.8 Hz, 2H), 8.12 (s, 1H), 8.05 (d, *J*=7.6 Hz, 2H), 4.11–4.16 (m, 2H), 1.12–1.21 (m, 3H); ¹³C NMR (100 MHz, DMSO): δ =170.4, 160.9, 154.3, 136.7, 130.4, 129.7, 129.4, 124.7, 122.0, 110.6, 60.6, 13.8; HRMS (ESI): m/z [M+H]⁺ calcd for C₁₄H₁₁F₆O₂N₂S: 385.04399; found: 385.04359.

4.3.29. Ethyl 2-amino-4-(furan-2-yl)thiazole-5-carboxylate (**7***j*). IR (KBr): 3452, 3270, 3115, 1699, 1631, 1511, 1478, 1302, 1273, 1170, 1145, 1119, 107.3, 1020 cm⁻¹; ¹H NMR (400 MHz, DMSO): δ =7.75 (s, 1H), 7.53 (s, 1H), 6.53 (s, 1H), 6.04 (s, 2H), 4.29 (br, 2H), 1.33–1.36 (br, 3H); ¹³C NMR (100 MHz, DMSO): δ =169.2, 147.9, 143.1, 115.2, 111.9, 60.9, 29.5, 14.4; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₀H₁₁O₃N₂S: 239.04849; found: 239.04811.

Acknowledgements

We thank the National Natural Science Foundation of China (Grants 20872042, and 201032001) and PCSIRT (No. IRT0953). We are also grateful to Xianggao Meng for his help with X-ray diffraction analysis.

Supplementary data

Supplementary data associated with this article can be found in online version, at doi:10.1016/j.tet.2011.10.074. These data include MOL files and InChiKeys of the most important compounds described in this article.

References and notes

- (a) Metzger, J. V. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Rees, C. W., Eds.; Pergamon: New York, NY, 1984; Vol. 6, pp 235–332; (b) Wang, W.-L.; Yao, D.-Y.; Gu, M.; Fan, M.-Z.; Li, J.-Y.; Xing, Y.-C.; Nan, F.-J. *Bioorg. Med. Chem. Lett.* 2005, 15, 5284; (c) Lewis, J. R. *Nat. Prod. Rep.* 1999, 16, 389; (d) Fink, B. A.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. *Chem. Biol.* 1999, 6, 205.
- (a) Haviv, F.; Ratajczyk, J. D.; DeNet, R. W.; Kerdesky, F. A.; Walters, R. L.; Schmidt, S. P.; Holms, J. H.; Young, P. R.; Carter, G. W. J. Med. Chem. **1988**, *31*, 1719; (b) Clemence, F.; Martret, O. L.; Delevallee, F.; Benzoni, J.; Jouanen, A.; Jouquey, S.; Mouren, M.; Deraedt, R. J. Med. Chem. **1988**, *31*, 1453; (c) Jaen, J. C.; Wise, L. D.; Caprathe, B. W.; Tecle, H.; Bergmeier, S.; Humblet, C. C.; Heffner, T. G.; Meltzner, L. T.; Pugsley, T. A. J. Med. Chem. **1900**, *33*, 311; (d) Tsuji, K.; Ishikawa, H. Bioorg. Med. Chem. Lett. **1994**, *4*, 1601.
- (a) Kearney, P. C.; Fernandez, M.; Flygare, J. A. J. Org. Chem. 1998, 63, 196; (b) Potewar, T. M.; Ingale, S. A.; Srinivasan, K. V. Tetrahedron 2008, 64, 5019.
- (a) Aoyama, T.; Murata, S.; Nagata, Y.; Takidoa, T.; Kodomari, M. *Tetrahedron Lett.* 2005, 46, 4875; (b) Aoyama, T.; Murata, S.; Arai, I.; Araki, N.; Takidoa, T.; Suzuki, Y.; Kodomari, M. *Tetrahedron* 2006, 62, 3201.
- Donohoe, T. D.; Kabeshov, M. A.; Rathi, A. H.; Smith, I. E. D. Synlett 2010, 2956.
 (a) Karade, H.; Sathe, M.; Kaushik, M. P. Catal. Commun. 2007, 8, 741; (b) Dodson, R. M.; Carroll King, L. J. Am. Chem. Soc. 1945, 67, 2242.
- For some recent reviews, see: (a) Tietze, L. F. Chem. Rev. 1996, 96, 115; (b) Ikeda, S. Acc. Chem. Res. 2000, 33, 511; (c) Walji, A. M.; MacMillan, D. W. C. Synlett 2007, 1477; (d) Zhu; bienaymé, H. Multicomponent reactions; Wiley-VCH: Eeinheim, 2005; (e) Domling, A. Chem. Rev. 2006, 106, 17; (f) Tejedor, D.; Garcia-Tellado, F. Chem. Soc. Rev. 2007, 36, 484.
- Yin, G. D.; Gao, M.; She, N. F.; Hu, S. L.; Wu, A. X.; Pan, Y. J. Synthesis 2007, 20, 3113; (b) Wang, Z. H.; Yin, G. D.; Qin, J.; Gao, M.; Cao, L. P.; Wu, A. X. Synthesis 2008, 22, 3675; (c) Yin, G. D.; Zhou, B. H.; Meng, X. G.; Wu, A. X.; Pan, Y. J. Org. Lett. 2006, 8, 2245; (d) Gao, M.; Yin, G. D.; Wang, Z. H.; Wu, Y. D.; Guo, C.; Pan, Y. J.; Wu, A. X. Tetrahedron 2009, 65, 6047.
- (a) Erian, A. W.; Sherif, S. M.; Gaber, H. M. Molecules 2003, 8, 793; (b) Friedrichsen, W. In Furans and Their Benzo Derivatives; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Comprehensive Heterocyclic Chemistry II; Pergamon, Elsevier Science: Oxford, 1996; Vol. 2, p 359; (c) Li, B.; Chiu, C. K.-F.; Hank, R. F.; Murry, J.; Roth, J.; Tobiassen, H. Org. Process Res. Dev. 2002, 6, 682.
- Compounds 5a-5f were synthesized via condensation of aromatic aldehyde and acetone in the presence of NaOH. See: Drake, N. L.; Allen, P., Jr. Org. Synth. Coll.; John Wiley & Sons: London, 1941; Vol. 1, pp 77–78.
- Crystal structure data for macrocycle **5b**: CCDC 834646. C₄₈H₄₈N₈S₄, chemical formula weight: 865.18, monoclinic, space group *P*2(1)/*n*, *a*=14.3676(16), *b*=17. 231(2), *c*=18.422(2)Å; *α*=90.000°, *β*=92.679(2)°, *γ*=90.00°, *U*=4555.8(9)Å³, *T*=200(2) K, *Z*=4, DC=1.261 Mg/M³, *μ*=0.252 mm⁻¹, *λ*=0.71073Å, *F*(000) 1824, crystal size 0.16×0.12×0.10 mm³, 8458 independent reflections[*R*(int)=0.0380], reflections collected 24,747, refinement method: full-matrix least-squares on *P*²: goodness-of-fit on *P*² 1.183, final *R* indices [*I*>2*a*(*I*)], *R*1=0.0734, *wR*2=0. 1544, largest diff. peak and hole 0.321Å⁻³ and -0.206 eÅ⁻³.